Understand the source comparison
5-Amino-1MQ for Weight Loss Without GLP-1: Comparison
Primary Target NNMT enzyme in adipose and hepatic tissue GLP-1 receptors in hypothalamus, pancreas, gut Dual pathway: central appetite + peripheral metabolism 5-amino-1MQ addresses mitochondrial substrate use; GLP-1 addresses intake regulation. Mechanistically
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Target
- NNMT enzyme in adipose and hepatic tissue
- GLP-1 receptors in hypothalamus, pancreas, gut
- Dual pathway: central appetite + peripheral metabolism
- 5-amino-1MQ addresses mitochondrial substrate use; GLP-1 addresses intake regulation. Mechanistically complementary
- Weight Loss Mechanism
- Increased mitochondrial NAD+, enhanced fat oxidation, SIRT1 activation
- Reduced gastric emptying, prolonged satiety signaling, decreased caloric intake
- Appetite suppression + metabolic efficiency
- GLP-1 has robust Phase 3 human data; 5-amino-1MQ has preclinical rodent data only. Evidence tiers differ substantially
- Appetite Effect
- No direct appetite suppression. Food intake unchanged in rodent models
- Significant appetite reduction. 20–30% caloric intake decrease typical
- GLP-1 component drives appetite control
- Combining these does not mean doubling weight loss. Mechanisms are additive, not synergistic
- Human Clinical Data
- Limited. No Phase 3 RCTs published as of 2026
- Extensive. STEP-1, SURMOUNT trials with 1,000+ participants
- Investigational only
- Researchers exploring combination protocols should stratify by baseline NNMT expression and insulin sensitivity
- FDA Approval Status
- Not FDA-approved; research-grade compound only
- FDA-approved for chronic weight management (Wegovy 2.4mg, Zepbound 15mg)
- Neither combination is FDA-approved
- Combining unapproved and approved agents introduces regulatory and safety complexity